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1. Introduction  
Although atherosclerosis seems to be continuously progressive and irreversible, it has been 
being demonstrated that substantial regression or stabilization of atherosclerotic lesions can 
occur by some interventions improving its determinants. However, the concepts of plaque 
regression or stabilization are not so new. It has been reviewed that the first reported 
observation of plaque regression could be found in the 1920s (Wissler, 1976), in which 
switching cholesterol-fed rabbits to low-fat chow over 2–3 years resulted in arterial lesions 
becoming more fibrous with a reduced lipid content. Later on, as the earliest prospective 
studies, a couple of previous studies in the 1950s have shown distinctive facts of plaque 
shrinkage or favorable change of its tissue components due to special diet therapy or some 
specific medications. In 1957 Friedman M et al. documented a result from prospective, 
interventional study demonstrating substantial shrinkage of atherosclerotic lesions 
performed in cholesterol-fed rabbits (Friedman, 1957). The dietary regimen raised total 
plasma cholesterol to around 1,000 mg/dl, and then animals received intravenous injections 
of phosphatidylcholine. They reported that after less than a week or so the size of the 
plaques as well as cholesterol stores within the arterial wall were significantly reduced. This 
striking report with some following supportive studies and reviews (Wissler, 1976; 
Armstrong, 1976; Malinow, 1983) has been surprisingly ignored for long years because of 
some beliefs regarding distinctive persistent characteristics of atherosclerosis, the negative 
history of which was reviewed by Stein Y, et al (Stein , 2001). However, various additional 
facts of plaque regression by some interventions have been demonstrated in other type of 
animal studies (Maruffo , 1968; Armstrong , 1970) since then without strong interests among 
general cardiologists. 
The first prospective study demonstrating plaque regression in humans might be the one 
documented by Ost CR, et al. in 1967(Ost, 1967). In the study, approximately 10% of patients 
treated with niacin showed improved femoral angiograms. Numerous additional larger 
trials of lipid lowering have then shown angiographic evidence of regression. However, 
though statistically significant, the resulted effects were very small (Brown, 1993), in which 
the improvement of percent stenosis of lumen were at most 2%. Accumulations of clinical 
evidences demonstrating the benefits of lipid-lowering in clinical outcome therefore yield 
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this kind of “angiographic paradox”. This paradox suggested that the improvement of 
clinical outcome was not necessarily associated with the improvement of arterial lumen 
diameter. However, various pathological findings have resolved this enigma. First, the 
answer came from the recognition of a phenomenon called as vascular remodling (Glagov, 
1987). The next answer was regarding the realization that lipid-rich, vulnerable plaques 
have a central role in acute coronary syndromes (Fuster, 1992; Libby, 1995). Vulnerable 
plaques are usually small in size and cause less than 50% occlusion. The vulnerable plaques 
are generally filled with intracellular and extracellular lipid, rich in macrophages and tissue 
factor, having low concentrations of smooth muscle cells as well as a thin fibrous cap (Shah, 
2003; Falk, 1995). Rupture of a vulnerable plaque provokes the formation of a robust 
thrombosis causing critical lumen occlusion. It has been estimated that lipid lowering, 
therapy does not induce lumen expansion but rather has most impact on risk reduction by 
the remodeling and stabilization of small, rupture-prone lesions. 
Based on these past histories, a new era of medication strategy had come in late 1980s with 
an appearance of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors (statins) in 
clinical setting. Many large-scale pivotal clinical trials have then shown that statins 
remarkably reduced both atherogenic lipoproteins as well as cardiovascular morbidity and 
mortality (Scandinavian Simvastatin Survival Study Group, 1994; Sacks, 1996; The Long-
Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group, 1998). 
However, the angiographic paradox still exists in this era even with a strong statin 
(Ballantyne, 2008). To overcome the paradox by in-vivo detection of plaque regression and 
stabilization, new development of commercially available intravascular imaging modalities 
contributed a lot to understanding the mechanism of statins for reducing cardiovascular 
events in patients with coronary artery disease. These modalities can visualize plaque size 
and its serial changes, and can even visualize tissue components within plaque to be able to 
estimate plaque vulnerability. 
In this chapter, readers will be able to describe the imaging mechanisms of intravascular 
ultrasound and coronary angioscopy especially for observing plaque regression and 
stabilization. Then, a variety of important evidences of plaque regression and stabilization 
evaluated by these systems will be introduced in order to understand the clinical feasibility 
of these modalities as well as to recognize current clinical cutting edge of knowledge 
regarding plaque regression and stabilization. 
2. Assessment of plaque regression and stability 
2.1 Assessment with intravascular ultrasound 
Intravascular ultrasound (IVUS) can provide gray-scale images with an accurate 
representation of plaque cross-sectional areas and volumes. Therefore, IVUS can follow in-
vivo plaque volumes serially in same patients. IVUS imaging is performed with an 
automatic catheter-pullback system to acquire consecutive cross-sections of arterial wall. 
Cross-sectional plaque area for each section can be measured by tracings of lumen-intima 
border as well as media-adventitia (External elastic membrane area: EEM area). The 
difference of the two areas corresponds to the plaque area (intima-media complex area). The 
product of a certain constant distance-related interval and the integration of these plaque 
areas calculated from each cross-section resulted in total plaque volume of interest. The 
certain interval varied from 0.1 mm to 10 mm according to the study concept. The IVUS 
indices used in major clinical trials were as follows: 1) Nominal Change of Percent Plaque 
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Volume: This is obtained from the absolute nominal change between the baseline and the 
follow-up period in percent value of plaque volume compared to EEM volume; 2) Percent 
Change in Plaque Volume: This is calculated from (follow-up plaque volume minus baseline 
plaque volume) divided by (follow-up plaque volume) times 100. It has been suggested that 
the former index might be more closely related to clinical outcome (Nicholls, 2010). 
However, this index would show “regression” even in case of increase in EEM volume 
(positive remodeling) without any change in plaque volume itself. The latter one may be 
more reflected to a particular change of a special plaque of interest. Although it has not yet 
been directly proved that these IVUS parameters are useful surrogate markers for clinical 
outcome, IVUS have demonstrated a remarkable change in plaque volume by use of statins. 
Furthermore, current technologies of IVUS can perform tissue characterization of plaque 
components with a color-coded image. In Japan, three color-IVUS systems are now 
commercially available. In addition, various other methods have been proposed with 
sophisticated mathematical models to detect tissue-specific acoustic properties. An overview 
of these methods is as follows. 
It was originally expected that tissue components within plaque could be identified from the 
video-intensity pattern of IVUS images. Subsequent studies, however, demonstrated 
significant limitations of tissue characterization by IVUS intensity patterns alone, especially 
in discriminating fibrous and fatty tissues or in assessing plaque vulnerability (Hiro, 1996; 
Hiro, 1997; Kimura, 1995; Jeremias, 1999). To overcome this limitation, special attempts to 
analyze the echo-signals including the raw radiofrequency (RF) ultrasound signal that 
comes from plaque segments. The echo signal, which is originally emitted as a pulse wave 
from the ultrasound catheter tip, is produced at the interface between the two materials 
having different acoustic impedances. There are several interfaces within plaque, so time-
series RF signal is then formed according to the degree of acoustic impedance mismatches 
and geometrical structure and distribution of each tissue components. Therefore, it can be 
expected that detection of special acoustic characteristics for each tissue component can 
allow us to visually identify it. Based upon this hypothesis, several successful studies have 
been reported, including the three commercially available machines. 
2.1.1 Integrated backscatter analysis (IB-IVUS®) 
This system visualizes the distribution of quantitative power or energy of echo for each 
segment of plaque using fast-Fourier transform of time-series RF signal. The total energy 
range is divided into four local ranges which correspond to four kinds of tissue components. 
This simple algorithm provides a high accuracy with a reliable sensitivity and specificity 
(Kawasaki , 2002).  
2.1.2 Autoregressive spectral analysis (Virtual histology®) 
The echo spectrum is first obtained by autoregressive spectral analysis for each portion of 
plaque. Autoregressive spectral analysis can obtain a spectrum of time-series signal, which 
has a different mathematical processing from fast-Fourier transform. Eight kinds of acoustic 
parameters are then measured for each spectrum. A classification tree which flows 
according to the values of the eight parameters makes the final diagnosis to discriminate 
four tissue types. The classification tree is already prepared with previous survey using 
tissue-known echo-samples (Nair, 2002). (Figure 1) 
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Fig. 1. VH-IVUS 
A pre-defined classification tree according to eight acoustic parameters identifies four kind 
of tissues. 
2.1.3 Attenuation-slope analysis 
The ultrasound energy is attenuated when running through tissues. The degree of 
attenuation depends upon the frequency. It is hypothesized that the frequency-dependence 
of ultrasound attenuation is different according to the tissue type. This system colorized the 
degree of frequency-dependent of ultrasound attenuation (Wilson , 1994). 
2.1.4 Angle-dependence analysis 
It has been demonstrated that intravascular ultrasound (IVUS) backscatter from fibrous 
tissue is strongly dependent on the ultrasound beam angle of incidence (Picano , 1985). It 
was found that this technique provides an accurate representation of the thickness of the 
fibrous cap in atherosclerotic plaque, the echo-intensity of which is highly angle-dependent 
(Hiro , 2001). (Figure 2) 
 
 
Fig. 2. Angle-dependence analysis 
Highly angle-dependent area (yellow) is accurately corresponded to fibrous cap. Incited 
from (Hiro, 2001)  
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2.1.5 Fractal analysis 
This method obtained the value of fractal dimension, which represents how complex the 
echo-segment is from each plaque portion. It was found that the echo-signal was more 
complex from lipidic tissue compared to fibrous tissue (Hiro, 2000). 
2.1.6 Wavelet analysis 
Wavelet analysis of RF IVUS signals is a novel mathematical model for assessing focal 
geometrical differences within arterial walls. Color coding of the wavelet correlation 
coefficient derived from the RF signal allows detection of changes in the geometrical profile 
of time-series signals to derive an image of plaque components (Figure 3). Murashige et al. 
showed that lipid-rich plaques could be detected with acceptable sensitivity and specificity 
using this method (Murashige, 2005). (Figure 3) 
 
 
Fig. 3. Wavelet analysis 
Wavelet correlation mapping of the RF signal from lipid-rich plaque revealed a unique 
stripe pattern. Incited from (Murashige, 2005) 
2.1.7 Neural network theory  
This method analyzes the RF signal with a self-learning system that resembles real neural 
actions in humans or animals. Kubota used a k-nearest neighbor method to classify tissue 
types of coronary plaque (Kubota , 2007). The k-nearest neighbor method is like a decision-
making system by a majority vote. When a time-series signal is evaluated, there are 
numerous parameters obtained by a signal-processing system. The parameters (total 
number = n) from a signal area of interest, therefore, can yield a coordinate as: 
(x1,x2,x3,…..xn) (Let’s call now point P). In such space, previously prepared coordinates 
obtained from the tissue-known signal exist around the point P. When you look around the 
point P for a constant distance, you can count the number of tissue-known points. If the 
majority of tissue-known points is from lipidic tissue, then the point P- corresponded tissue 
area is considered to be a lipidic tissue. Kubota R et al. modified this k-nearest method to 
enhance the accuracy of tissue characterization by IVUS. Sathyanarayana S, et al. performed 
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this kind of analysis in analyzing spectral similarity of the RF signal (Sathyanarayana , 
2009). It was hypothesized that each tissue component has a special characteristic spectrum 
shape. This system is now commercially available with a system name, iMap ® (Figure 4). 
This system can identify four kinds of tissue, which definitions are slightly different from 
the one used in VH-IVUS. The imaging system is unique, in which the confidence level of 
identification of tissue types is represented the brightness of each color corresponded to 
each tissue type. The brightness of confidence level represents the degree of majority in the 
decision-making space of the k-nearest neighbor method.  
 
 
Fig. 4. iMap system. 
The system of iMap perform color mapping of four different tissue types. Confidence level 
of each tissue identification is reflected on the brightness of each color. CL:Confidence level 
2.2 Assessment with coronary angioscopy 
Coronary angioscopy provides a full-color perspective of the intravascular surface 
morphology of plaque. This technique also accurately represents the presence of thrombi.  
In this method, vulnerable plaques are detected as yellow plaques compared to the normal 
surface which is depicted as white. The degree of yellow grade of the plaque surface  
is corresponded to how rich lipidic components are under the plaque surface or how  
thin the thickness of fibrous cap is within the plaque. It has been documented that  
the degree of yellowness of plaque as well as the number of yellow plaque observed are 
related to plaque vulnerability and poor patient prognosis in cardiovascular outcome  
(Kodama , 2000; Ueda , 1997; Ueda , 2004; Naghavi , 2003; Asakura , 2001; Ohtani , 2006; 
Mizuno, 1992). This modality together with IVUS has provided various aspects of plaque 
regression and its stability.  
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2.3 Problems in assessing plaque vulnerability 
Naghavi M, and a lot of famous investigators collaborated to try to establish the criteria for 
defining vulnerable plaques(Naghavi , 2003). As the major criteria, the plaque with the 
following characteristics can be identified as vulnerable plaque: 
• Active inflammation (monocyte/macrophage and sometimes T-cell infiltration) 
• Thin cap with large lipid core 
• Endothelial denudation with superficial platelet aggregation 
• Fissured plaque 
• Stenosis more than 90% 
As the minor criteria: 
• Superficial calcified nodule 
• Glistening yellow by coronary angioscopy 
• Intraplaque hemorrhage 
• Endothelial dysfunction 
• Outward (positive) remodelling 
So what criteria can we examine generally in all patients? 
IVUS and coronary angioscopy can actually represent the thickness of thin fibrous cap and 
the volume of lipid-rich core. However, Imoto K, et al demonstrated in the study with a 
biomechanical simulation of in-plaque stress distribution that plaques with the same 
thickness of fibrous cap does not necessarily indicate the same vulnerability to rupture 
(Imoto, 2005). Ambrose JA documented a get-to-the-point criticism in search of the 
vulnerable plaque(Ambrose, 2008). He proposed several prerequisites to establish the way 
to identify vulnerable plaque for distinctive improving patient vulnerability. 
1. “Vulnerable plaque” caused by a thin-capped fibroatheroma can be identified with 
modern technology. 
2. A “vulnerable plaque” caused by plaque erosion should be identifiable. 
3. The number of “vulnerable plaques” is known, and the number is limited. 
4. The natural history of a “vulnerable plaque” has been identified in patients treated with 
optimal systemic therapies. 
5. An interventional approach applied locally or regionally to an asymptomatic“vulnerable 
plaque” is proven to reduce future events relative to the best systemic medical therapy. 
He criticized that among these prerequisites, only the first is currently possible, but the 
others are not yet established and require further study. We have to realize that thin-capped 
fibro-atheroma is not a single cause of acute coronary syndrome. Erosion, inflammatory cell 
infilitration, intraplaque hemorrhage or local endothelial dysfunction should be also 
evaluated. Fukumoto Y, et al. has reported that color mapping of shear stress along plaque 
surface using IVUS images is useful for identifying future rupture point(Fukumoto, 2008), 
since it was found that local concentration of shear stress is related to a trigger of plaque 
rupture. Therefore, numerous local risk factor should be considered for identifying the 
vulnerable plaque. Even when the method is established, still we have additional problems. 
We have to possess a detailed data on the likelihood of a cardiac event for a proven 
“vulnerable plaque.” For example, if only 5% of a given plaque type as identified will develop 
an event on follow-up, all 20 of these plaques will need to be treated with a new procedure to 
prevent 1 event, that is, NNT=20(Ambrose, 2008). Is this allowed in using the expensive stent 
therapy? Therefore, a well-designed clinical trial should be performed to prove the clinical 
feasibility of preventive therapy for a particular plaque which is identified as vulnerable.  
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3. Clinical evidences using intravascular imagings 
A number of human studies in a single center demonstrated the beneficial effects of statin or 
other lipid-lowering drugs in plaque progression/regression and stabilization. For example, 
Takagi T, et al. documented in 1997 as one of the earliest reports on IVUS observation that 
administration of pravastatin reduced serum lipid levels and progression of coronary artery 
atherosclerotic plaque(Takagi, 1997). Kawasaki et al. reported with use three-dimensional 
color mapping of tissue components with IB-IVUS system that statin therapy reduced the 
lipid component in patients with stable angina without reducing the degree of 
stenosis(Kawasaki, 2005). Previous coronary angioscopic studies have demonstrated that 
statin therapy stabilizes yellow color grade of coronary plaques (Takano, 2003).  
Using IVUS and/or coronary angioscopy, various human multicenter trials with statins 
have offered important information on plaque regression. In the following paragraphs, the 
trials including REVERSAL(Nissen , 2004), ASTEROID(Nissen , 2006), ESTABLISH(Okazaki, 
2004), JAPAN-ACS(Hiro, 2009), COSMOS(Takayama, 2009), TWINS(Hirayama, 2009) and 
TOGETHAR(Kodama, 2010) are overviewed and discussed. These trials demonstrated not 
only the degree of regressive effects of statins on plaque, but also key determinants and 
mechanisms of plaque regression.  
3.1 The REVERSAL study (The Reversal of Atherosclerosis with Aggressive Lipid 
Lowering trial) (Nissen, 2004) 
This was to compare the 18-month effect of regimens designed to produce intensive lipid 
lowering or moderate lipid lowering on coronary artery atheroma burden and progression. 
Patients with stable coronary artery disease were randomly assigned to receive a moderate 
lipid lowering regimen consisting of 40 mg of pravastatin or an intensive lipid-lowering 
regimen consisting of 80 mg of atorvastatin. The primary efficacy parameter was the 
percentage change in atheroma volume (follow-up minus baseline). Baseline low-density 
lipoprotein cholesterol level (mean, 150.2 mg/dL in both treatment groups) was reduced to 
110 mg/dL in the pravastatin group and to 79 mg/dL in the atorvastatin group (P<0.001). It 
was shown that progression of coronary atherosclerosis occurred in the pravastatin group 
(median change = 2.7%; 95% CI:0.2% to 4.7%; P=0.001) compared with baseline. Progression 
did not occur in the atorvastatin group (−0.4%; CI−2.4% to 1.5%; P=0.98) compared with 
baseline. It was concluded that for patients with coronary heart disease, intensive lipid-
lowering treatment with atorvastatin reduced progression of coronary atherosclerosis 
compared with pravastatin. In this study, remarkable regression of plaque by statin was not 
yet clearly indicated.  
3.2 The ASTEROID study (A study to Evaluate the Effect of Rosuvastatin  
on Intravascular Ultrasound-Derived Coronary Atheroma Burden)  
(Nissen, 2006) 
This study was to assess whether very intensive statin therapy could regress coronary 
atherosclerosis as determined by IVUS imaging. Patients with stable coronary artery disease 
received intensive statin therapy with rosuvastatin, 40 mg/day. Two primary efficacy 
parameters were prespecified: the change in percent atheroma volume (PAV) and the 
change in nominal atheroma volume in the 10-mm subsegment with the greatest disease 
severity at baseline (observation period: 24 months). Baseline low-density lipoprotein 
cholesterol level (mean, 130.4 mg/dL) was reduced to 60.8 mg/dL (P<0.001). For the 
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primary efficacy parameter of PAV, the mean decrease was −0.98% and the median was 
−0.79% (P<0.001 compared with baseline). For the second primary efficacy parameter, 
change in atheroma volume in the 10-mm subsegment with the greatest disease severity, the 
mean change was −6.1 mm3, and the median change was −5.6 mm3  (P<0.001 compared 
with baseline). This change represents a median reduction of 9.1% in atheroma volume in 
the 10-mm segment with the greatest disease severity. It was concluded that very high-
intensity statin therapy using rosuvastatin 40 mg/day achieved significant regression of 
atherosclerosis .In this study, remarkable regression of plaque by statin was first clearly 
indicated as a multicenter study result. Regression can be considered to be a completely 
different process from inhibition of progression, so this result was striking.  
3.3 The ESTABLISH study (Early Statin Treatment in Patients with Acute Coronary 
Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by 
Serial Volumetric Intravascular Ultrasound Analysis during Half a Year after Coronary 
Event) (Okazaki, 2004) 
This was a single-center, but should be discussed, since the results was historical. Most 
unique part of this study was study population. This study investigated the 6-month effect 
of early statin treatment by atorvastatin of 20 mg daily on plaque volume of a nonculprit 
lesion by serial volumetric intravascular ultrasound in patients with ACS. All patients who 
underwent emergency coronary angiography and percutaneous coronary intervention were 
randomized to intensive lipid-lowering therapy (n=35; atorvastatin 20 mg/day) or control 
(n=35) groups after PCI. Volumetric intravascular ultrasound analyses were performed at 
baseline and 6-month follow-up for a non-PCI site in 48 patients (atorvastatin, n=24; control, 
n=24). LDL-C level was significantly decreased by 41.7% (124.6 to 70.0 mg/dL) in the 
atorvastatin group compared with the control group, in which LDL-C was not significantly 
changed (123.9 to 119.4 mg/dL) (atorvastatin vs. control : P<0.0001). Plaque volume was 
significantly reduced in the atorvastatin group (mean 13.1% decrease) compared with the 
control group (8.7 % increase; P<0.0001). These results of the degree of plaque regression by 
statin were surprisingly remarkable compared to the former reports from foreign countries 
for patients with stable coronary artery disease. This evidence was then proved by the 
JAPAN-ACS study which is discussed next.  
3.4 The JAPAN-ACS study (Japan Assessment of Pitavastatin and Atorvastatin in 
Acute Coronary Syndrome) (Hiro, 2009) 
This study had almost similar protocol for selecting patients with acute coronary syndrome 
and measuring protocol to the ESTABLISH study. Major difference was that this was a non-
inferiority test with randomization between patients with taking atorvastatin 20 mg/day 
and patients with pitavastatin of 4 mg/day. Therefore, based on the ESTABLISH study, the 
objective of this study was to evaluate whether the regressive effects of aggressive lipid-
lowering therapy with atorvastatin on coronary plaque volume in patients with acute 
coronary syndrome are generalized for other statins in multicenter setting (observation 
period:8-12 months) . The primary end point was the percentage change in nonculprit 
coronary plaque volume. Baseline low-density lipoprotein cholesterol level (mean, 133.8 and 
130.9 mg/dL in atorvastatin, and pitavastatin groups, respectively) was reduced to 84.1 
mg/dL (-35.8% decrease: P<0.001, compared to the baseline) in the atorvastatin group and 
to 81.1 mg/dL (-36.2% decrease: P<0.001)in the pitavastatin group. The mean percentage 
change in plaque volume was -18.1% and -16.9 % (p=0.5) in the pitavastatin and atorvastatin 
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groups, respectively, which was associated with negative vessel remodeling. The upper 
limit of 95% confidence interval of the mean difference in percentage change in plaque 
volume between the two groups did not exceed the pre-defined noninferiority margin of 
5%, suggesting noninferiority between the two groups. It was thus proved that the efficacies 
of both group were equivalent in the percent change of plaque volume. This results 
supported the data of the ESTABLISH study that early administration of statins after the 
onset of ACS has the potential to reverse the process of atherosclerosis.This observation also 
generalized the effect of statins other than atorvastatin on plaque volume in the setting of 
ACS. The reason why plaques in Japanese patients with ACS shows greater regression by 
statin compared to the foreign patients with stable coronary artery disease might be shown 
by the COSMOS study which is summarized later. 
Recently interesting results came from a sub-analysis of the JAPAN-ACS study (Hiro , 2010). 
It demonstrated that the regression of coronary plaque induced by statin therapy after ACS 
was weaker in diabetic patients than their counterparts, although the reduction of LDL-C 
level was similar between diabetic group and non-diabetic group. In addition, it was also 
interesting that significant correlation between % change of PV and low-density lipoprotein 
cholesterol (LDL-C) level was found in patients with diabetes mellitus (n=73, P<0.05, r=0.4), 
whereas there was no significant correlation between the 2 parameters in patients without 
diabetes mellitus (n=178). This study was suggesting that there might be LDL-C dependent 
mechanism and LDL-C non-depedent mechanism in plaque regression by statin. It might be 
possible that in diabetic patients LDL-C non-dependent mechanism is inhibited by 
unknown mechanism resulting smaller regression of plaque volume. The mechanism of 
plaque regression may have various steps and pathways.  
3.5 The COSMOS study (The Coronary Atherosclerosis study Measuring  
Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese  
Subjects) (Takayama, 2009) 
This study was the first multicenter study on IVUS observation of plaque with use of statin 
for Japanese patients with stable coronary artery disease. This was as a single arm 76-week 
study to investigate the effect of rosuvastatin on plaque volume in such patients. The 
patients received first rosuvastatin 2.5mg/day, which could be increased at 4-week intervals 
to ≤20 mg/day. The primary end point was the percentage change in nonculprit coronary 
plaque volume. The change in the serum low-density lipoprotein-cholesterol level from 
baseline to end of follow-up was –38.6±16.9% (mean:140.2 to 82.9 mg/dL, P<0.0001). Percent 
change of plaque volume, the primary endpoint, was –5.1±14.1% (P<0.0001). The degree of 
plaque regression compared to the degree of reduction of LDL-C level was just in-between 
the results from the foreign patients with stable coronary artery disease and the ones from 
Japanese patients with acute coronary syndrome (Figure 5). Therefore, Japanese patients as 
well as patients with acute coronary artery disease can easily show regression of plaque 
volume compared to the foreign patients and patients with stable coronary artery disease, 
respectively. This might be due to the difference in plaque tissue characteristics. It has been 
reported that patients with ACS have many greater-risk nonculprit plaques(Asakura , 2001; 
Burke , 1997).  
3.6 The TWINS study (Hirayama, 2009)  
This study as well as the TOGETHAR study were using not only IVUS but also coronary 
angioscopy to examine the effect of statin on plaque characteristics. The aim of this study  
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Fig. 5. Meta-regressive analysis of the relationship between LDL-C level and the percent 
change of plaque volume.  
Some data was not the result as the primary endpoint of the study, which was  
re-estimated by documented data. Black line represents the meta-regression curve for the 
foreign patients with stable coronary artery disease. Red line represents the one for Japanese 
patients with ACS. The data of the COSMOS study is just in-between the two lines.  
See each protocol and result for each study from the papers by (Takano , 2003; Nissen ,  
2004; Nissen , 2006; Okazaki , 2004; Hiro , 2009). The data of A-PLUS was obtained from  
the paper by (Berry , 2007). ATV:atorvastatin, PRV:pravastatin, RSV:rosuvastatin, 
PTV:pitavastatin. 
was to elucidate 80-week time course of atorvastatin-induced changes in vulnerable plaque 
using angioscopy and intravascular ultrasound (IVUS). Patients with coronary artery 
disease received atorvastatin of 10-20 mg/day. Mean baseline LDL-C level of 144.4 mg/dL 
was significantly reduced to 86.4 mg/dL at week 28 and to 89.4 mg/dL at week 80. 
Angioscopic images were classified into 6 grades (0–5) based on yellow color intensity. The 
mean angioscopic grade of 58 yellow plaques significantly decreased from 1.5 (95% 
confidence CI: 1.2 to 1.8) to 1.1 (95%CI 0.9 to 1.3, P=0.012) at week 28 and 1.2 (95%CI :0.9 to 
1.4, P=0.024) at week 80, compare to the baseline (no significant difference between week 28 
and week 80). Mean volume of 30 lesions, including the 58 yellow plaques, significantly 
reduced –8.3% (95%CI: –11.5 to –5.2) at week 28 (P<0.001 for baseline vs week 28) and –
17.8% (95%CI –23.9 to –11.8) at week 80 (P<0.001) for baseline vs week 80. It should be noted 
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that qualitative changes in plaque occurred relatively early after the beginning of 
atorvastatin therapy (by week 28), and that quantitative changes in atheroma volume 
occurred continuously, even after week 28, up to week 80. These non-parallel results suggest 
that there may be two different, probably independent, mechanisms involved in the 
reduction of vulnerability, improvement in characteristics, and reduction of the volume of 
yellow plaques. These different time courses suggested that the improvement in plaque 
characteristics occurs early, whereas atheroma volume regression occurs over a prolonged 
period of time.  
3.7 The TOGETHAR study (Kodama, 2010) 
This multicenter study also revealed that the stabilization and regression of 
atherosclerotic plaques by statin may differ. This study was performed to assess coronary 
plaque regression and stabilization following 52 weeks of pitavastatin treatment (2 
mg/day). Low-density lipoprotein-cholesterol (LDL-C) was reduced 34.5% (mean: 145.0 
to 93.6 mg/dl, P<0.001). Yellow grade decreased (2.9±0.8 to 2.6±0.7, P=0.040) during  
52 weeks. However, percent atheroma volume on IVUS did not change during 52 weeks. 
It was concluded that fixed dose pitavastatin stabilized vulnerable coronary plaques  
by the reduction of yellow grade without significant reduction of plaque volume. The  
fact that plaque volume was not significantly changed was probably due to the 
characteristics patient populations that did not include patients with ACS. These results 
suggested that plaque stabilization and plaque regression reflect independent processes 
mediated by different mechanisms, which has been previously reported(Kawasaki , 2005; 
Schartl , 2001).  
4. Future perspectives 
Recently new intravascular imaging modalities have been proposed, including optical 
coherence tomography. Furthermore, noninvasive imaging system, such as multi-detector 
CT and MRI, can visualize coronary plaques more vividly than before. Therefore, brilliant 
future in terms of plaque imaging can be expected. We may have to produce the following 
future as: Fully understanding of the plaque regression and stabilization in terms of changes 
in tissue component; Perfect prediction of plaque rupture with an absolute value of its 
likelihood within a certain period; More detailed elucidation of mechanism of acute 
coronary syndrome, which is fully imaged by some imaging modalities; Best therapeutic 
ways which are clarified based on the data of plaque imaging. Therefore, the research world 
of plaque imaging for plaque regression and stability has still a wide variety of clinical 
goals. 
5. Conclusion 
Advanced developments in the field of intravascular ultrasound and angioscopy are 
offering their capabilities of accurately measuring plaque volume as well as identifying 
tissue components. These technologies significantly help understand in vivo pathological 
reactions of plaque by lipid-lowering therapy especially in plaque regression and 
stabilization. Furthermore, these technologies are providing numerous reliable evidences 
with multicenter studies.  
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